Lexaria Bioscience Corp.
NASDAQ Capital MarketTotal Valuation
Lexaria Bioscience Corp. carries a market capitalization of 11.32M, placing it among publicly traded companies globally. Its enterprise value stands at 14.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.32M |
| Enterprise Value | 14.17M |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 73.05 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -2.48 |
| P/OCF Ratio | -2.45 |
Enterprise Valuation
| EV / Sales | 73.05 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lexaria Bioscience Corp. maintains a current ratio of 32.88, meaning it holds 32.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 32.88 |
| Quick Ratio | 29.40 |
| Debt / Equity | 7.97 |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -170.32 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 4,389.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Lexaria Bioscience Corp.'s stock has declined approximately -42.90722% over the past 52 weeks. The 50-day moving average sits at 0.60, while the 200-day moving average is 0.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -42.90722% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 0.78 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lexaria Bioscience Corp. generated 194,000.00 in revenue and converted that into -5.74M in net income, yielding earnings per share of -0.24. EBITDA reached -5.66M, while operating income came in at -5.71M.
| Revenue | 194,000.00 |
| Gross Profit | 194,000.00 |
| Operating Income | -5.71M |
| Pretax Income | -5.74M |
| Net Income | -5.74M |
| EBITDA | -5.66M |
| EBIT | -5.71M |
| Earnings Per Share (EPS) | -0.24 |
Cash Flow
Lexaria Bioscience Corp. produced -5.79M in operating cash flow over the past twelve months. After subtracting -75,620.00 in capital expenditures, free cash flow totaled -5.87M - equivalent to -0.25 per share.
| Operating Cash Flow | -5.79M |
| Capital Expenditures | -75,620.00 |
| Free Cash Flow | -5.87M |
| FCF Per Share | -0.25 |
Margins
Lexaria Bioscience Corp. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,945.43 and net profit margin of -2,959.19 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -2,945.43 |
| Pretax Margin | -2,960.35 |
| Profit Margin | -2,959.19 |
| EBITDA Margin | -2,915.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -45.99 |
| FCF Yield | -40.32 |
Stock Splits
Lexaria Bioscience Corp.'s most recent stock split took place on January 12, 2021 with a 30:1 split ratio.
| Last Split Date | 1/12/2021 |
| Split Ratio | 30:1 |
Scores
Lexaria Bioscience Corp. posts an Altman Z-Score of -26.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.30 |